Evaluation of efficacy and safety of romosozumab administration group and ibandronate sodium hydrate administration group for osteoporosis patients after denosumab treatment
Not Applicable
Recruiting
- Conditions
- osteoporosis
- Registration Number
- JPRN-UMIN000037394
- Lead Sponsor
- Shinshu University School of Medicine Dept. of Orthopaedic Surgery
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 60
Inclusion Criteria
Not provided
Exclusion Criteria
1. If you had previously been treated with romosozumab, ibandronate sodium hydrate 2. If you are allergic to romosozumab, ibandronate sodium hydrate 3. Those who have hypocalcemia 4. For pregnant women or women who are nursing 5.Patients with disorders that delay esophageal passage such as esophageal stricture or achalasia 6.Patients who can not keep standing or sitting for more than 60 minutes when taking 7. Those with severe renal dysfunction (eGFR 30 ml / min / less than 1.73 m2) or those receiving dialysis 8.Patients with upper digestive tract disorder such as dysphagia, esophagitis, gastritis, duodenitis, ulcer etc. 9. Other patients who the research director judged inappropriate as a subject
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method